In the ECHELON-1 trial, brentuximab vedotin, an anti-CD30 conjugate, was compared to ABVD when added to AVD (A + AVD), showing higher rates of neutropenia, especially in patients aged > 60 years [41]. The gene discussed is TNFRSF8; the disease is Decreased total neutrophil count.